Appili Therapeutics Stock Key Fundamental Indicators

APLI Stock  CAD 0.02  0.01  20.00%   
As of the 17th of February 2026, Appili Therapeutics shows the Risk Adjusted Performance of 0.0635, mean deviation of 9.32, and Downside Deviation of 20.57. Appili Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Appili Therapeutics Total Revenue

109,734

Appili Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Appili Therapeutics' valuation are provided below:
Gross Profit
100.4 K
Market Capitalization
M
Enterprise Value Revenue
71.6082
Revenue
100.4 K
Earnings Share
(0.02)
We have found one hundred twenty available fundamental signals for Appili Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Appili Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 17th of February 2026, Enterprise Value is likely to grow to about 21.8 M, while Market Cap is likely to drop about 4.6 M. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
At this time, Appili Therapeutics' Tax Provision is very stable compared to the past year.
  

Appili Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.6 M2.7 M4.9 M
Pretty Stable
Short and Long Term Debt Total14.8 M14.1 M4.1 M
Slightly volatile
Other Current Liabilities64.8 K68.2 K439 K
Slightly volatile
Total Current Liabilities19 M18 M5.2 M
Slightly volatile
Property Plant And Equipment Net16.3 K17.1 K46.9 K
Slightly volatile
Accounts Payable3.2 M4.7 M2.3 M
Slightly volatile
Cash1.1 M1.1 M3.2 M
Pretty Stable
Non Current Assets Total16.3 K17.1 K46.9 K
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile
Long Term Debt804.2 K846.5 K1.3 M
Slightly volatile
Cash And Short Term Investments1.1 M1.1 M3.5 M
Pretty Stable
Net Receivables1.2 M1.9 M1.1 M
Slightly volatile
Common Stock Shares Outstanding74.6 M139.5 M59.2 M
Slightly volatile
Long Term Debt Total804.2 K846.5 K1.3 M
Slightly volatile
Liabilities And Stockholders Equity2.6 M2.7 M4.9 M
Pretty Stable
Non Current Liabilities Total804.2 K846.5 K1.3 M
Slightly volatile
Capital Surpluse17.9 M17 M4.8 M
Slightly volatile
Other Current Assets219.6 K131.7 K154.4 K
Slightly volatile
Other Stockholder Equity17.9 M17 M5.5 M
Slightly volatile
Total Liabilities19.8 M18.9 M6.5 M
Slightly volatile
Total Current Assets2.6 M2.7 M4.8 M
Pretty Stable
Common Stock30.4 M48.7 M20.7 M
Slightly volatile
Property Plant Equipment16.3 K17.1 K46.9 K
Slightly volatile
Common Stock Total Equity15.8 M24.1 M15.6 M
Slightly volatile
Short and Long Term Debt14 M13.3 M2.7 M
Slightly volatile
Capital Stock36.7 M48.7 M24 M
Slightly volatile
Property Plant And Equipment Gross85.1 K74.6 K114.8 K
Slightly volatile

Appili Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization11.3 K12.1 K12.6 K
Pretty Stable
Selling General Administrative3.5 M3.3 M2.5 M
Slightly volatile
Selling And Marketing Expenses122.8 K129.3 K274.3 K
Slightly volatile
Other Operating Expenses318.2 K335 K5.7 M
Very volatile
Research Development7.8 M8.4 M5.6 M
Slightly volatile
Cost Of Revenue11.2 K12.3 K12.1 K
Very volatile
Total Operating Expenses318.2 K335 K5.6 M
Very volatile
Reconciled Depreciation11.7 K12.1 K15.6 K
Slightly volatile

Appili Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation128.7 K135.5 K434.8 K
Pretty Stable
Depreciation11.3 K12.1 K12.6 K
Pretty Stable
Capital ExpendituresK2.1 K22.2 K
Slightly volatile
Total Cash From Financing Activities165.6 K174.3 K4.1 M
Very volatile
End Period Cash Flow1.1 M1.1 M3.2 M
Pretty Stable
Change To Netincome4.3 M4.1 M1.6 M
Slightly volatile
Begin Period Cash Flow80.8 K85 K3.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio40.4848.5978.4647
Slightly volatile
Days Sales Outstanding5.7 K5.5 K1.5 K
Slightly volatile
Average Payables2.8 MM2.6 M
Slightly volatile
Stock Based Compensation To Revenue1.721.351.9391
Slightly volatile
Capex To Depreciation0.190.21.9297
Slightly volatile
EV To Sales14413769.5171
Pretty Stable
Inventory Turnover0.140.180.1801
Slightly volatile
Days Of Inventory On Hand2.2 K2.1 KK
Slightly volatile
Payables Turnover0.00280.00290.0091
Slightly volatile
Sales General And Administrative To Revenue26.8425.5715.9224
Pretty Stable
Research And Ddevelopement To Revenue68.9865.724.026
Slightly volatile
Capex To Revenue0.01490.02110.0105
Slightly volatile
Cash Per Share0.01110.01160.0824
Very volatile
Days Payables Outstanding136.6 K130.1 K75.9 K
Slightly volatile
Current Ratio0.210.222.8749
Slightly volatile
Receivables Turnover0.06570.06910.5911
Slightly volatile
Capex Per Share0.00.07.0E-4
Slightly volatile
Average Receivables1.3 M916.6 K1.4 M
Slightly volatile
Revenue Per Share9.0E-40.0010.0066
Very volatile
Interest Debt Per Share0.120.13030.05
Slightly volatile
Debt To Assets3.833.651.2771
Slightly volatile
Operating Cycle5.7 K5.5 K2.3 K
Slightly volatile
Days Of Payables Outstanding136.6 K130.1 K75.9 K
Slightly volatile
Ebt Per Ebit12.912.292.9736
Slightly volatile
Quick Ratio0.210.222.8637
Slightly volatile
Net Income Per E B T0.760.910.8656
Slightly volatile
Cash Ratio0.08550.091.9446
Slightly volatile
Days Of Inventory Outstanding2.2 K2.1 KK
Slightly volatile
Days Of Sales Outstanding5.7 K5.5 K1.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0243
Slightly volatile
Fixed Asset Turnover5.766.079.689
Slightly volatile
Debt Ratio3.833.651.2771
Slightly volatile
Price Sales Ratio40.4848.5978.4647
Slightly volatile
Asset Turnover0.02830.02980.0745
Slightly volatile
Gross Profit Margin0.780.880.9635
Slightly volatile

Appili Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.6 M4.9 M20 M
Slightly volatile
Enterprise Value21.8 M17.6 M21.1 M
Pretty Stable

Appili Fundamental Market Drivers

Forward Price Earnings2.3776
Cash And Short Term Investments1.2 M

Appili Shares Outstanding Driver Correlations

Understanding the fundamental principles of building solid financial models for Appili Therapeutics is extremely important. It helps to project a fair market value of Appili Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Appili Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Appili Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Appili Therapeutics' interrelated accounts and indicators.
Understanding that Appili Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Appili Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Appili Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.

Appili Therapeutics 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Appili Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Appili Therapeutics.
0.00
11/19/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/17/2026
0.00
If you would invest  0.00  in Appili Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Appili Therapeutics or generate 0.0% return on investment in Appili Therapeutics over 90 days. Appili Therapeutics is related to or competes with XORTX Therapeutics, and Aptose Biosciences. Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for... More

Appili Therapeutics Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Appili Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Appili Therapeutics upside and downside potential and time the market with a certain degree of confidence.

Appili Therapeutics Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Appili Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Appili Therapeutics' standard deviation. In reality, there are many statistical measures that can use Appili Therapeutics historical prices to predict the future Appili Therapeutics' volatility.
Hype
Prediction
LowEstimatedHigh
0.000.0213.49
Details
Intrinsic
Valuation
LowRealHigh
0.000.0213.49
Details

Appili Therapeutics February 17, 2026 Technical Indicators

Appili Therapeutics Backtested Returns

Appili Therapeutics appears to be out of control, given 3 months investment horizon. Appili Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0649, which signifies that the company had a 0.0649 % return per unit of risk over the last 3 months. By analyzing Appili Therapeutics' technical indicators, you can evaluate if the expected return of 0.87% is justified by implied risk. Please makes use of Appili Therapeutics' Mean Deviation of 9.32, downside deviation of 20.57, and Risk Adjusted Performance of 0.0635 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Appili Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of -0.0864, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Appili Therapeutics are expected to decrease at a much lower rate. During the bear market, Appili Therapeutics is likely to outperform the market. Please check Appili Therapeutics' standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Appili Therapeutics' price patterns will revert.

Auto-correlation

    
  0.07  

Virtually no predictability

Appili Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Appili Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Appili Therapeutics price movement. The serial correlation of 0.07 indicates that barely 7.0% of current Appili Therapeutics price fluctuation can be explain by its past prices.
Correlation Coefficient0.07
Spearman Rank Test0.24
Residual Average0.0
Price Variance0.0
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Appili Common Stock Shares Outstanding

Common Stock Shares Outstanding

74.63 Million

At this time, Appili Therapeutics' Common Stock Shares Outstanding is very stable compared to the past year.
Based on the latest financial disclosure, Appili Therapeutics has 121.27 M of shares currently outstending. This is 32.83% lower than that of the Biotechnology sector and 13.49% higher than that of the Health Care industry. The shares outstanding for all Canada stocks is 78.79% higher than that of the company.

Appili Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Appili Therapeutics's current stock value. Our valuation model uses many indicators to compare Appili Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Appili Therapeutics competition to find correlations between indicators driving Appili Therapeutics's intrinsic value. More Info.
Appili Therapeutics is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Appili Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Appili Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Appili Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Appili Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Appili Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Appili Therapeutics could also be used in its relative valuation, which is a method of valuing Appili Therapeutics by comparing valuation metrics of similar companies.
Appili Therapeutics is currently under evaluation in shares outstanding category among its peers.

Appili Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Appili Therapeutics from analyzing Appili Therapeutics' financial statements. These drivers represent accounts that assess Appili Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Appili Therapeutics' important valuation drivers and their relationship over time.
202120222023202420252026 (projected)
Market Cap65.7M8.0M4.5M4.2M4.9M4.6M
Enterprise Value6.3M9.7M12.3M15.3M17.6M21.8M

Appili Fundamentals

About Appili Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Appili Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Appili Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Appili Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue54.2 K56.9 K
Total Revenue115.5 K109.7 K
Cost Of Revenue12.3 K11.2 K
Stock Based Compensation To Revenue 1.35  1.72 
Sales General And Administrative To Revenue 25.57  26.84 
Research And Ddevelopement To Revenue 65.70  68.98 
Capex To Revenue 0.02  0.01 
Ebit Per Revenue(1.71)(1.80)

Pair Trading with Appili Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Appili Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Appili Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Appili Stock

  0.4DOS Dios ExplorationPairCorr
  0.37ETG Entree ResourcesPairCorr
  0.35NICU Magna MiningPairCorr
  0.35CU-PH Canadian Utilities Earnings Call Next WeekPairCorr
  0.33LOVE Cannara BiotechPairCorr
The ability to find closely correlated positions to Appili Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Appili Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Appili Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Appili Therapeutics to buy it.
The correlation of Appili Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Appili Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Appili Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Appili Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Appili Stock

Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.